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Abstract
AIM
To investigate the impact of physical frailty on risk 
of hospitalisation in cirrhotic patients on the liver 
transplant waitlist.
METHODS
Cirrhotics listed for liver transplantation at a single 
centre underwent frailty assessments using the Fried 
Frailty Index, consisting of grip strength, gait speed, 
exhaustion, weight loss, and physical activity. Clinical 
and biochemical data including MELD score as collected 
at the time of assessment. The primary outcome was 
number of hospitalised days per year; secondary out-
comes included incidence of infection. Univariable and 
multivariable analysis was performed using negative 
binomial regression to associate baseline parameters 
including frailty with clinical outcomes and estimated 
incidence rate ratios (IRR). 
RESULTS
Of 587 cirrhotics, 64% were male, median age (inter-
quartile range) was 60 (53-64) years and MELD score 
was 15 (12-18). Median Fried Frailty Index was 2 
(1-3); 31.6% were classified as frail (fried frailty ≥ 3). 
During 12 mo of follow-up, 43% required at least 1 
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hospitalisation; 38% of which involved major infection. 
107/184 (58%) frail and 142/399 (36%) non-frail 
patients were hospitalised at least once (P  < 0.001). In 
univariable analysis, Fried Frailty Index was associated 
with total hospitalisation days per year (IRR = 1.51, 
95%CI: 1.28-1.77; P  ≤ 0.001), which remained sig-
nificant on multivariable analysis after adjustment for 
MELD, albumin, and gender (IRR for frailty of 1.21, 
95%CI: 1.02-1.44; P  = 0.03). Incidence of infection 
was not influenced by frailty.
CONCLUSION
In cirrhotics on the liver transplant waitlist, physical 
frailty is a significant predictor of hospitalisation and 
total hospitalised days per year, independent of liver 
disease severity.
Key words: Hospitalisation; Infection; Cirrhosis; Frailty; 
Transplantation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This study demonstrates a significant inde-
pendent link between bedside measures of physical 
frailty and risk for hospitalisation in cirrhotic patients on 
the liver transplant waitlist. This adds to previous data 
showing a link between frailty and mortality in cirrhosis, 
and therefore allows us to better select at-risk cirrhotic 
patients who are most in need of more intense chronic 
disease management programs.
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INTRODUCTION
The most commonly used tool to prioritise patients 
for liver transplantation is the MELD or MELD-sodium 
score[1], which fails to capture the decline in systemic 
health suffered by many liver transplant candidates. 
This is particularly relevant as liver transplant reci-
pients are ageing and accumulating comorbidities[1]. 
Muscle wasting and weakness are incredibly common, 
observed in up to 70% of waitlisted individuals[2]. Both 
quantitative measures of muscle mass and functional 
measures of muscle strength have been associated 
with waitlist mortality, infection and post-transplant 
complications[3-5]. 
Frailty is a multi-system disorder that is classically 
associated with ageing, disability and comorbidity, and 
is known to increase the risk for falls, hospitalisation 
and mortality[6]. Quantification of frailty is most co-
mmonly performed using the Fried Frailty Index. Initially 
designed for use in geriatric populations, the Fried Frailty 
Index encompasses handgrip strength, exhaustion, gait 
speed, unintentional weight loss and physical activity[7]. 
Some data suggest that functional measures of muscle 
strength may better predict outcomes in cirrhotics than 
CT-based measures of sarcopenia[8]. Furthermore, frailty 
measures can be performed at the bedside, without 
the need for ionising radiation, which makes them 
preferable for repeated measures to assess changes 
over time. This is important as progression of frailty is 
itself associated with poorer outcome[9].
Physical frailty as measured the by Fried Frailty 
Index has previously been identified as a risk factor 
for mortality in cirrhosis[3,4], yet there are little data 
investigating the impact of frailty on hospitalisation 
in cirrhosis. An independent link between low muscle 
mass and infection risk has been identified pre-liver 
transplantation[5,10], as well as increased hospitalisation 
days[11], and thus similar findings may be expected for 
frailty. 
This study aims to evaluate the impact of frailty 
on total number of hospitalisation days. The ultimate 
goal is to identify an at-risk subset of the cirrhotic 
population to assist in the development of preventative 
strategies to improve outcomes in this vulnerable po-
pulation. 
MATERIALS AND METHODS
We report a single-centre prospective observational 
cohort study of 587 pre-transplant cirrhotics, performed 
at the University of California, San Francisco, between 
July 2012 and December 2014.
Subjects
All adult (≥ 18 years) cirrhotic subjects actively listed 
for liver transplantation for cirrhosis are invited to enrol 
in the ongoing prospective Functional Assessment in 
Liver Transplantation (FrAILT) study. Ninety-seven 
percent of invited participants enrol in this study. 
Enrolment occurs in the outpatient setting as described 
previously[3]. All patients provided written informed 
consent. Major exclusion criteria include inability to 
consent due to severe encephalopathy (numbers 
count > 120 s), prior transplantation due to the impact 
of immunosuppressants on muscle function, as well 
as transplant listing for reasons other than cirrhosis. 
Patients with incomplete frailty testing measures 
at baseline or lost-to-follow-up at 12 mo were also 
excluded.
Baseline variables
At study entry, patient demographics including age, sex, 
disease aetiology, and medical comorbidities (including 
hepatocellular carcinoma, diabetes, coronary artery 
disease and HIV infection) were recorded. Standard 
baseline biochemical parameters were retrieved from 
electronic medical records including liver function 
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tests to calculate MELD score, coagulation profile, full 
blood count and electrolyte profile. Clinical information 
regarding the presence of ascites, ascertained by the 
patient’s primary hepatologists, was recorded. Hepatic 
encephalopathy was assessed using the numbers 
connection test, with a score > 35 s indicating the pre-
sence of encephalopathy[12].
Frailty assessments
Assessments of physical frailty were performed in 
the outpatient setting using the Fried Frailty Index, 
consisting of grip strength, gait speed, exhaustion, 
weight loss, and physical activity. Frail was defined as 
Fried Frailty Index ≥ 3 points out of a maximum of 5. 
These assessments have been validated in geriatric 
and cirrhotic populations[3,7,9,13].
Short physical performance battery (SPPB) assess-
ment was also undertaken as a second measure to 
validate findings using the Fried Frailty Index. The 
SPPB comprises gait speed, standing balance (ability 
to perform a tandem stand) and chair stands (time 
taken to complete 5 chair stands. Frail is defined as a 
SPPB score ≤ 9. This score has also been associated 
with poor outcome in cirrhosis[3].
Outcomes
The primary outcome was number of hospitalised 
days per year during the 12 mo follow-up period 
immediately following the frailty assessment. This 
was determined from medical records at the home 
institution and review of external medical records in 
the case of hospital admissions elsewhere. Patients 
who died or were transplanted within 12 mo were 
censored at this time (n = 82). 
Secondary outcomes included number of hospitali-
sations over 12 mo, length of stay per hospitalisation, 
and hospitalisation for major infection. Infection was 
defined according to NACSELD (North American 
Consortium for Studies of End-Stage Liver Disease) 
criteria[14], to avoid inadvertent inclusions of subjects 
receiving empirical antibiotic therapy for liver decom-
pensation. 
Alternate causes of hospitalisation were listed as 
hepatic encephalopathy, acute kidney injury, ascites, 
gastrointestinal bleeding or other, according to hospital 
discharge records. 
Statistical analysis
The statistical review of the study was performed by 
a biomedical statistician. Descriptive statistics are 
displayed as the median [interquartile range (IQR)] 
unless stated otherwise. Wilcoxon rank-sum and χ 2 
tests compared frail vs non-frail and hospitalised vs 
non-hospitalised patients,
Univariable negative binomial regression evaluated 
the association of frailty with hospitalisation days per 
year and estimated incidence rate ratios (IRR) and 
95%CI. Variables significant at the 0.2 level and below 
were included in the multivariate model. Backward 
elimination (p > 0.05 for removal) was used to select 
the final multivariable model.
Logistic regression was used to evaluate the 
relationship between hospitalisation for infection and 
frailty. Bivariable regression models estimated OR and 
95%CIs for each factor while accounting for observation 
time. Characteristics with a bivariable p value below 
0.2 were assessed in the multivariable model to allow 
for consideration of all possible contributing factors. 
Backward elimination (p > 0.05 for removal) identified 
the subset of variables associated with hospitalisation 
for infection while adjusting for observation time. Frailty 
(Fried Frailty Index ≥ 3) was included in the final 
model as the predictor of interest.
A cut-off p value less than 0.05 was used to deter-
mine statistical significance. Analyses were performed 
in SAS 9.4 (SAS Institute, Cary NC).
RESULTS
616 consecutive cirrhotic patients were enrolled into 
the FrAILT study between July 2012 and February 
2015. 587 (95%) of these patients had complete 
data for analysis in this study. The median (IQR) age 
was 60 (53-64) years, BMI 28.2 (24.8-33.1) cm/m2, 
and median MELD score was 15 (12-18) and 64.2% 
were male. Fifty-seven percent were Caucasian, 26% 
Hispanic, 7% Asian, 4% African American, and 6% 
were of other ethnicity. Four patients had missing Fried 
Frailty Index. Thirty-one point six percent of patients 
were classified as frail, as defined by a Fried Frailty 
Index of 3 or above. Frail patients had more severe 
liver failure than non-frail patients as measured by 
MELD score and features of decompensation, and 
lower rates of hepatocellular carcinoma. Frail patients 
were slightly but significantly older than non-frail 
patients. Baseline demographics by frailty group are 
described in Table 1. 
Outcomes
During the 12 mo study period, 43% of subjects re-
quired at least 1 hospitalisation. The primary reason 
for hospitalisation was infection in 39%, hepatic 
encephalopathy in 19%, acute kidney injury or ascites 
in 16%, GI bleeding in 8% or other miscellaneous 
cause in 19%. In those patients requiring hospitalisation 
(n = 243, for eight hospitalised patients the number 
of hospitalisations is unknown), 54% had a single 
hospitalisation, 33% had 2 or 3 hospitalisations, and 
13% had 4 or more hospitalisations. The median (IQR) 
length of stay per hospitalisation was 4.5 (3.0-7.5) d. 
Risk factors for hospitalisation
Using a Fried Frailty Index of ≥ 3, frail patients were 
significantly more likely to be hospitalised, with 58% 
of frail and 36% of non-frail patients hospitalised 
at least once in the subsequent 12-mo period (p < 
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0.001. 
On univariable analysis, the Fried Frailty Index, 
as a continuous variable, was associated with total 
hospitalisation days per year (IRR = 1.51, 95%CI: 
1.28-1.77; p < 0.001). This remained significant on 
multivariable analysis after adjustment for MELD, 
albumin, and female sex (IRR = 1.21, 95%CI: 1.02-1.44; 
p = 0.03). Table 3 displays the significant results of the 
negative binomial regression model.
Risk factors for infection
Twenty percent of frail patients compared to 15% of 
non-frail patients experienced infection (p = 0.09). On 
bivariable analysis (incorporating time to outcome), 
the point estimates were suggestive of an increased 
odds of infection for frail vs non-frail patients although 
statistical significance was not achieved by SPPB or 
Fried Frailty Index (Table 4). There was however a 
significantly reduced odds of infection in patients 
who could complete 5 chair stands within 10 s (p = 
0.046). In addition, the MELD score was significantly 
associated with the incidence of infection, and serum 
albumin and the presence of hepatocellular carcinoma 
were inversely associated with infection. There was 
no significant relationship for other factors, including 
the presence of ascites (OR = 1.15, p = 0.570), HIV 
infection (OR = 1.53, p = 0.464) or diabetes (OR = 0.98, 
p = 0.939). 
On multivariable analysis, only serum albumin 
(OR = 0.39, 95%CI: 0.26-0.58, p < 0.001) and the 
0.001). Frail patients had more hospitalisation [median 
1 hospitalisation (0-2) vs 0 hospitalisations (0-1), p < 
0.001] and spent more days in hospital than non-frail 
patients [median 3 (0-8.2) d vs 0 (0-4) d, p < 0.001]. 
The significant differences between patients who 
were hospitalised compared with not hospitalised 
within 12 mo are displayed in Table 2. Walk speed was 
slower (median 1.2 vs 1.3 metres/second), handgrip 
strength was lower (median 27.7 kg vs 32.7 kg) and 
chair stands completed per second was also lower 
in hospitalised patients (median 0.4 stands/s vs 0.5 
stands/s), indicating greater frailty. Females were more 
likely to be hospitalised than men (51% vs 38%, p = 
0.003). Subjects who were hospitalised were marginally 
younger than those who were non-hospitalised (median 
age 59 vs 60 years, p = 0.02).
Among patients with at least one hospitalisation, 
the median (IQR) length of stay per hospital admission 
was similar by frailty status [5 (3.0-8.0) d for frail vs 
4 (3.0-6.3) d for non-frail, p = 0.24]. For patients ho-
spitalised for infection, the median (IQR) length of 
stay was longer, at 6 (3.5-8.3) d, as compared to 3.5 
(2.2-6.0) d for those hospitalised for other causes, p < 
Table 1  Baseline demographics of waitlisted cohort enrolled into the FrAILT study stratified by frail (Fried Frailty Index ≥ 3) and 
non-Frail (Fried Frailty Index < 3)
Characteristic Overall (n  = 587) Frail (n  = 184) Non-frail (n  = 399) P  value
Age (yr) 60 (53-64) 60 (54-64) 59 (52-63)  0.03
Male 64% 60% 66%  0.12
BMI (kg/m2) 28 (25-33) 28 (25-33) 28 (25-33)  0.74
MELD (points) 15 (12-18) 16 (14-20) 14 (12-17) < 0.001
Albumin (g/dL)  3.0 (2.6-3.5)  2.9 (2.5-3.2)  3.2 (2.7-3.6) < 0.001
Sodium (nmol/L)   137 (134-139)   135 (132-138)    137 (135-139) < 0.001
HCC 33% 25% 36%    0.004
Numbers connection test (s) 40 (30-54) 46 (34-61) 38 (29-51) < 0.001
Ascites 28% 40% 22% < 0.001
HIV      2.9%      2.7%      3.0%  0.85
Diabetes 31% 32% 30%  0.46
BMI: Body mass index; MELD: Model for end stage liver disease; HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus.
Table 2  Significant differences between patients hospitalised 
within 12 mo and non-hospitalised individuals
Characteristic Hospitalised, 
n  = 251
Non-hospitalised, 
n  = 336
P value
Age (yr) 59 (53; 63) 60 (55; 64)  0.02
Male gender 57% 69%    0.003
MELD score 16 (13; 20) 14 (11; 17) < 0.001
Albumin (g/dL) 2.8 (2.5; 3.2) 3.2 (2.8; 3.7) < 0.001
Sodium (mmol/L) 136 (133; 139) 137 (135; 139)    0.002
Fried Frailty Index 2 (1; 3) 2 (1; 2) < 0.001
SPPB score 11 (9; 12) 11 (10; 12) < 0.001
Chair stands per second 0.4 (0.3-0.5) 0.5 (0.4-0.6) < 0.001
Walk speed (m/s) 1.2 (0.9-1.4) 1.3 (1.1-1.6) < 0.001
Handgrip strength (kg) 27.7 (21.7; 35.3) 32.7 (25.0; 40.9) < 0.001
Encephalopathy (numbers 
connection score)
41.6 (31.7; 57.3) 38.3 (29.4; 52.1)    0.008
MELD: Model for end stage liver disease; SPPB: Short physical performance 
battery.
Table 3  Significant predictors of hospitalisation days per 12 
mo on multivariable analysis
Characteristic IRR (95%CI), n  = 583 P value
Frail by Fried Frailty Index 1.21 (1.02, 1.44)  0.03
MELD score 1.10 (1.06, 1.15) < 0.001
Albumin (g/L) 0.43 (0.31, 0.61) < 0.001
Female sex 1.85 (1.22, 2.81)    0.004
Frail-Fried Frailty Index ≥ 3. IRR: Incidence rate ratios; MELD: Model for 
end-stage liver disease.
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presence of hepatic encephalopathy (OR = 0.59, 
95%CI: 0.36-0.95, p = 0.03) remained significant 
predictors of infection. Frailty, as measured by the Fried 
Frailty Index, was not significant in this model (OR = 
1.30 Fried Frailty Index ≥ 3 vs < 3, 95%CI: 0.80-2.12, 
p = 0.29). 
DISCUSSION
This prospective study, including nearly 600 patients with 
cirrhosis awaiting liver transplantation, demonstrates 
that functional measures of frailty are associated with 
increased hospitalisation days independent of the 
MELD score. The increase in hospitalisation observed 
in this study was due to an increased incidence of 
hospitalisation, predominantly for complications of end-
stage liver disease. These data from the ongoing FrAILT 
study add critical information to our prior report on 
the significant association between frailty and waitlist 
mortality[3] by providing an intermediate outcome of 
hospitalisation. The clinical implication of this finding 
is that functional frailty measures performed in the 
outpatient setting can identify patients who may 
benefit from tailored interventions to reduce the risk of 
subsequent hospitalisations and ultimately, death.
Our data have important implications for the 
management of patients with cirrhosis, who impose a 
high burden on the health care system with frequent 
exacerbations of their chronic disease. In particular, 
implementation of a chronic disease model of care 
for decompensated cirrhotics has strong potential to 
improve outcomes in this population[15]. Indeed, in 
one study in Italy, case management was shown to 
significantly reduce both the 30 d re-hospitalisation 
rate as well as overall mortality, while reducing cost[16]. 
Given the resource requirements of such a program 
it is not practical or feasible to suggest that every 
cirrhotic should be enrolled, therefore a simple frailty 
measure such as the Fried Frailty Index is useful in its 
ability to select patients who are most in need of such 
an intensive management strategy. Perhaps even more 
importantly, frailty represents a potentially modifiable 
outcome through focused pre-habilitation programs 
that specifically target the individual components that 
contribute to the frail phenotype[17]. Demonstrating 
that frailty is associated with increased hospitalisations 
provides strong justification to develop and implement 
such programs early in the disease progression to 
prevent hospitalisation and subsequent deterioration in 
this vulnerable population. 
In our cohort, frailty was not significantly associated 
with infection on multivariable analysis, although there 
was a trend to increased infection. This differs from 
previous research demonstrating that sarcopenia, a 
major contributor to the frail phenotype, has previously 
been shown to increase risk of infection-related 
hospitalisations[10]. It may be that frailty represents 
an early phenotype, whereas sarcopenia represents 
more established systemic disturbance that may be 
required for infection risk. However in the absence 
of longitudinal data incorporating frailty measures 
and body composition measurements, this cannot 
be confirmed. It may also be that quantification of 
hepatic encephalopathy in this cohort by the numbers 
count test, a feature recognised to be closely related 
to frailty[18], allowed us to better ascertain the relative 
contributions of different factors to infection risk 
than previous studies. The lack of an independent 
association between frailty and infection was somewhat 
surprising, and further studies are required to clarify 
this issue. 
The majority of hospital admissions in our cohort 
were indeed for liver-related decompensation including 
infection, but also acute kidney injury, hepatic ence-
phalopathy and hepatorenal syndrome (81%), and 
thus could be expected to accelerate the progression 
of liver disease. This sheds important insight into the 
potential mechanisms of the impact of frailty on adverse 
health outcomes in cirrhotics: instead of increasing the 
likelihood of any single complication, frailty decreases 
a patient’s reserve to withstand any of the typical 
complications of cirrhosis, increasing the severity of the 
complications and the likelihood of inpatient admission.
Limitations of this study include its observational 
nature, albeit prospective, therefore the impact of 
reversing frailty cannot be proven. However the con-
sistent associations between frailty and poor outcome 
suggest that it is indeed itself a contributing factor, and 
the finding that deterioration in frailty further increases 
risk of mortality adds further weight to this argument[9]. 
Furthermore, data from a study of patients undergoing 
TIPS insertion suggest that reversing muscle wasting 
can indeed improve survival[19]. An additional limitation 
is the inability to accurately classify the cause for 
non-infectious hospital admissions in this study, to 
determine whether the increase in hospitalisation was 
due to a specific factor, such as hepatic encephalopathy. 
Most episodes of decompensation of liver disease are 
multifactorial in nature, the specific triggering factor 
may never be identified, and standardised diagnostic 
Table 4  Predictors of infection on bivariable analysis 
(accounting for observation time)
Characteristic OR (95%CI) P  value
Albumin (g/dL) 0.40 (0.27-0.60) < 0.001
MELD score 1.07 (1.02-1.11)    0.005
HCC (yes vs no) 0.60 (0.36-0.99)    0.046
Chair stands (completion of 5 
chair stands within 10 s)
0.32 (0.11-0.98)    0.046
Age (yr) 0.98 (0.96-1.0)  0.05
Frail (SPPB score ≤ 9) 1.54 (0.94-2.50)  0.08
Frail (Fried frailty Index ≥ 3) 1.49 (0.94-2.36)  0.09
Sodium 0.96 (0.90-1.01)  0.10
Hepatic encephalopathy 
(numbers connection > 45 s)
0.72 (0.46-1.14)  0.16
MELD: Model for end stage liver disease; HCC: Hepatocellular carcinoma; 
SPPB: Short physical performance battery.
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criteria are lacking. Finally, this study was single-centre, 
and thus validation in other cohorts is required.
Strengths of this study include a large study po-
pulation that is representative of transplant waitlist 
cohorts with a high study uptake of 97% of patients 
assessed for transplantation, with near-complete (95%) 
longitudinal data. We therefore believe that these 
results are representative of a tertiary centre transplant 
waitlist. Despite the study limitations, our identification 
of a relationship between frailty - as measured by a 
simple tool that can easily and rapidly be performed 
in the clinic setting - a significantly increased risk 
of hospitalisation has important implications for the 
management of patients with cirrhosis. The Fried Frailty 
Index can help clinicians identify those at greatest 
risk of hospitalisation and thus in greatest need of 
chronic liver disease management programs to provide 
additional support. 
In conclusion, physical frailty in subjects on the liver 
transplant waitlist, as measured by the Fried Frailty 
Index, is a significant predictor of 12 mo hospitalisation 
days independent of liver disease severity. This findings 
adds to the previously established link between frailty 
and mortality. These data provide us with a strong 
rationale to develop pre-habilitation and chronic di-
sease management programs for frail patients on the 
transplant waitlist to reduce hospitalisation, reduce 
mortality and reduce healthcare costs. 
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